A Systematic Review of Potential Therapeutic Use of Lycium Barbarum Polysaccharides in Disease

Table 3

Translational studies demonstrating the topical/local therapeutic effects of LBP.

Source	Country	Groups	Sample size	Method	Parameter(s)	Outcomes	Remarks
Cornea and Ocular Surface effects
Chien et al. 2018 [39]	Taiwan	Rats: Control vs GBE 250 mg/kg/body weight vs GBE 350mg/kg/bw vs GBE 500mg/kg/bw	45	In vivo	Schirmer’s test	1.3±0.4 mm vs 7.4±1.8 mm vs 8.2±1.5 mm vs 9.4±0.5 mm (all at 3 weeks)	Demonstrates potential role of
					Tear break-up time	<5 s vs 7.2±2.4s vs 7.9±2.4s vs 8.8±1.2 s (all at 3 weeks)
					KC fluorescein staining	Control mild, moderate and severe grade 37.5, 37.5, and 25.0% vs LBP treated mild, moderate and severe grade 82.5, 12.5, and 5.0% after 3 weeks treatment
Du et al. 2017 [38]	China	Rat corneal cell line: Control vs sham vs UVB−/LBPs+ vs UVB+/LBPs− vs UVB+/LBPs+	None	In vitro	Cell viability	5mg/ml LBP increased but 10mg/ml reduced viability	Promising results but the effect on human keratocytes should be assessed
					Cell apoptosis	UVB+/LBPs−(47.06% ± 1.83%) vs UVB+/LBPs+ (13.93% ± 1.76%)
Total papers: 2

Abbreviations. a-Goji berry extract (GBE), body weight (bw), lycium barbarum polysaccharide (LBP), ultraviolet radiation B rays (UVB), and b-keratoconjunctival (KC).